circRNAs as prognostic markers in pediatric acute myeloid leukemia

Cancer Lett. 2024 Jun 1:591:216880. doi: 10.1016/j.canlet.2024.216880. Epub 2024 Apr 15.

Abstract

Circular RNAs (circRNAs) arise from precursor mRNA processing through back-splicing and have been increasingly recognized for their functions in various cancers including acute myeloid leukemia (AML). However, the prognostic implications of circRNA in AML remain unclear. We conducted a comprehensive genome-wide analysis of circRNAs using RNA-seq data in pediatric AML. We revealed a group of circRNAs associated with inferior outcomes, exerting effects on cancer-related pathways. Several of these circRNAs were transcribed directly from genes with established functions in AML, such as circRUNX1, circWHSC1, and circFLT3. Further investigations indicated the increased number of circRNAs and linear RNAs splicing were significantly correlated with inferior clinical outcomes, highlighting the pivotal role of splicing dysregulation. Subsequent analysis identified a group of upregulated RNA binding proteins in AMLs associated with high number of circRNAs, with TROVE2 being a prominent candidate, suggesting their involvement in circRNA associated prognosis. Through the integration of drug sensitivity data, we pinpointed 25 drugs that could target high-risk AMLs characterized by aberrant circRNA transcription. These findings underscore prognostic significance of circRNAs in pediatric AML and offer an alternative perspective for treating high-risk cases in this malignancy.

Keywords: Circular RNA; Pediatric acute myeloid leukemia; Prognosis; RNA binding proteins; RNA splicing dysregulation.

MeSH terms

  • Biomarkers, Tumor* / analysis
  • Child
  • Child, Preschool
  • Datasets as Topic
  • Gene Expression Profiling
  • Gene Expression Regulation, Leukemic
  • Humans
  • K562 Cells
  • Leukemia, Myeloid, Acute* / drug therapy
  • Leukemia, Myeloid, Acute* / genetics
  • Prognosis
  • Progression-Free Survival
  • RNA, Circular* / analysis
  • Sequence Analysis, RNA
  • Survival Analysis
  • Treatment Outcome

Substances

  • RNA, Circular
  • Biomarkers, Tumor